Browsing Tag
Ltd.
78 posts
CXMT secures reported $3bn Tencent memory deal ahead of major China IPO
CXMT has reportedly secured a $2.94 billion Tencent memory deal before its major China IPO. Discover what it means for AI chips and global suppliers.
Micron (NASDAQ: MU) revenue quadruples to $41.5bn as AI memory shortage drives record margins
Micron revenue quadrupled to $41.46 billion as AI memory demand drove record margins and $100 billion in contracts. Read what comes next for $MU now.
SK hynix targets $29.4bn Nasdaq raise as AI memory investment accelerates
SK hynix plans a historic $29.4 billion Nasdaq raise to expand AI memory capacity. Discover what the listing means for Nvidia, Micron and Samsung.
Sprintex stock jumps 19% as TSMC trial tests ASX: SIX growth story
TSMC opened the door, but Sprintex still has to fund the factory floor. A paid trial now tests whether ASX: SIX can convert prestige into scale.
QuantumScape stock loses Honda spike as QS faces scale test
Honda validated QuantumScape’s battery, but QS has lost 7.7% since the rally. Eagle Line manufacturing now decides whether confidence returns.
Could Skyworks’ Qorvo debt exchange clear a key path for the chip deal?
Find out how Skyworks’ Qorvo debt exchange could affect SWKS stock, merger risk and semiconductor consolidation strategy today!
TSMC is powering the AI boom, so why is Washington suddenly making investors nervous?
Find out how TSMC’s Washington patent fight could affect TSM stock, AI chip demand, export controls, and U.S. semiconductor policy.
Xbox may be heading for major layoffs, but is Microsoft fixing gaming or shrinking it?
Find out how Microsoft’s reported Xbox layoffs could reshape MSFT stock sentiment, Game Pass strategy, console sales, and gaming margins.
Can Kelun-Biotech and Merck turn sac-TMT into the first ADC plus immunotherapy standard in front-line lung cancer?
Merck needs life after Keytruda. Kelun-Biotech’s sac-TMT lung cancer data may show how the next oncology cycle takes shape.
Dizal Pharmaceutical deepens NSCLC pipeline case as DZD6008 and golidocitinib data sharpen ASCO 2026 focus
Read how Dizal’s ASCO 2026 NSCLC data for DZD6008 and golidocitinib could reshape its lung cancer pipeline strategy today!